Photocure announces positive results of Phase 2B study evaluating Visonac in acne

12-Jun-2012 - Photocure ASA announced the results of the phase 2b study in acne with Visonac (methyl aminolevulinate 80mg/g), a topical acne treatment. In this study, Visonac showed a statistically significant reduction in inflammatory lesions and overall improvement in acne severity.The phase 2b trial was a ...

Photocure announces the achievement of the second transition milestone of EUR 1.5 million for Hexvix

07-Mar-2012 - Photocure ASA announced the achievement of the second manufacturing transition milestone from Ipsen, its new strategic partner for commercializing Hexvix worldwide, excluding the US and Nordic region. This triggers a payment of EUR 1.5 million. Hexvix is Photocure’s flagship product to aid in ...

Photocure announces the achievement of the first transition milestone for Hexvix

13-Oct-2011 - Photocure ASA announced the achievement of the first transition milestone from Ipsen, its new strategic partner for commercializing Hexvix worldwide, excluding the US and Nordic region.Photocure and Ipsen announced a new strategic collaboration for the commercialization of Hexvix. In accordance ...

Photocure initiates enrolment into phase II trial of Cevira® for cervical HPV infection

First study to evaluate optimal dose of novel integrated drug-delivery device

21-Jun-2011 - Photocure ASA has initiated patient enrolment in the first trial to evaluate the optimal dose and safety of Cevira, an integrated intravaginal drug-delivery device.The study is a randomized, placebo controlled dose finding study in patients with low to moderate grade cervical intraepithelial ...

Photocure: Hexvix/Cysview demonstrates long term benefit

Results from 5.5 year follow up of recurrence of bladder cancer

16-May-2011 - Photocure announced the results from a 5.5 year follow up of recurrence in patients with Non Muscle Invasive Bladder Cancer( NMIBC) showing a long term benefit of the use of Hexvix compared to patients who received white light cystoscopy alone. After a follow-up up period up to 5.5 years, the ...

Photocure announces successful Phase II results for Cevira

28-Jan-2011 - Photocure announced final six month follow up results from its phase IIa study with Cevira® in patients with low-grade precancerous lesions of the cervix. The results showed a complete removal of intracervical lesions in over 50% of patients enrolled in the trial.Photocure also announces that ...

Allumera shows significant improvements in appearance of skin compared to light

30-Nov-2010 - Photocure announced positive preliminary results from its consumer trial on Allumera™, demonstrating that the product can improve the appearance of skin. The RevitAll ™ study was designed to determine the ability of Allumera™ cream to improve the appearance of skin compared to illumination by ...

Hexvix guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer

07-Oct-2010 - Photocure announces a publication in Journal of Urology on Hexvix. This publication shows that Hexvix guided fluorescence cystoscopy (Hexvix®), as an adjunct to conventional white-light cystoscopy, improves the detection of bladder cancer and reduces the rate of early tumour recurrence, compared ...

Photocure announces successful Phase II results for Cevira

05-Oct-2010 - Photocure announced promising initial results in a Phase II study of Cevira(TM) in treatment of patients with mild cervical abnormalities. Photocure is developing Cevira(TM) for the non-surgical treatment of cervical HPV infection and precancerous lesions of the cervix. Cevira(TM) is a ...

Photocure announces results from phase II study in acne with Visonac

31-May-2010 - Photocure announced results from its phase II study in acne with Visonac(TM) in combination with its new full face acne lamp. The efficacy results received in the last phase II study in acne with a simplified VisonacTM procedure were not as good as phase II results previously obtained with ...